Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bifidobacterium carbohydrate transporters and metabolic enzymes represent a complex suite of proteins responsible for the degradation and utilization of complex glycans in the human gut (Pokusaeva et al., 2011, PubMed: 21415361). These bacteria utilize specialized ATP-binding cassette (ABC) transporters and phosphotransferase systems (PTS) to internalize various oligosaccharides, which are then processed by a diverse array of glycosyl hydrolases, such as beta-galactosidases and alpha-glucosidases (O'Callaghan & van Sinderen, 2016, PubMed: 27303377). A hallmark of this metabolism is the "bifid shunt," centered on the enzyme fructose-6-phosphate phosphoketolase, which efficiently converts hexoses into acetate and lactate (Turroni et al., 2018, PubMed: 29445130). By fermenting non-digestible dietary fibers and human milk oligosaccharides, these enzymes play a crucial role in maintaining gut homeostasis and supporting the development of the infant immune system (Sela et al., 2008, PubMed: 19047636). While not traditional drug targets for inhibition, they are primary targets for prebiotic interventions aimed at selectively increasing Bifidobacterium populations to treat conditions like inflammatory bowel disease and metabolic syndrome (Gibson et al., 2017, PubMed: 28611480). Therapeutic strategies focus on providing specific carbohydrate substrates that match the enzymatic repertoire of beneficial Bifidobacterium strains to promote the production of health-promoting short-chain fatty acids (Rivière et al., 2016, PubMed: 27375568). This metabolic activity also contributes to the "barrier effect," preventing the colonization of the gut by pathogenic microorganisms (Fukuda et al., 2011, PubMed: 21270894).
Selective fermentation of prebiotic substrates to promote beneficial bacterial growth and produce health-promoting short-chain fatty acids (SCFAs)
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bifidobacterium carbohydrate transporters and metabolic enzymes.